Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of solbinsiran in adults with severe hypertriglyceridemia
CTR20260546Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia comparing solbinsiran with placebo (2 arms). Primary endpoint: Change from baseline in triglyceride level. Started Apr 2026; status: active.
02
Drugs
solbinsiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20260546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260546.